Biopharma Facing Two Major Crises - A Huge Patent Cliff And Price Controls

Theoretically, biopharma should be in the midst of major growth to position itself for even greater things. Instead, it is facing two major threats that will likely limit its future potential. The first is a looming patent cliff which is the biggest in its history. As described by Meagan Parrish in PharmaVoice, 190 drugs accounting for $236 billion in sales will lose patent exclusivity by 2030. Included in this list are some of the biggest selling drugs of all time like AbbVie’s Humira, Merck’s Keytruda and Lilly’s Trulicity.